Actively Recruiting
Phase 3 Open-label Study to Assess Depemokimab as Add-on Treatment for Asthma with Type 2 Inflammation in Children Aged 6 to 11 Years
Led by GlaxoSmithKline · Updated on 2026-08-26
34
Participants Needed
3
Research Sites
90 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating depemokimab as an additional treatment for asthma with type-2 inflammation in children aged 6 to 11 years. This Phase 3 open-label study aims to understand how depemokimab is processed by the body, how it works, and its safety and tolerability in this young population. The trial focuses on children with a specific eosinophilic asthma phenotype who require regular asthma treatment. Participants will receive depemokimab doses adjusted based on their body weight. The medication is administered as a subcutaneous injection and will be given as an add-on maintenance therapy alongside their usual asthma treatments. The study lasts up to 52 weeks, during which participants receive the study drug and are monitored regularly. During the study, participants will have their blood levels of depemokimab measured, and safety will be assessed through monitoring adverse events, laboratory parameters, vital signs, and immune responses. Researchers will also track changes in blood eosinophil counts to evaluate the drugs effects. Regular visits and assessments will support close monitoring of participant health throughout the year-long study.
CONDITIONS
Brief Title
A Study of Depemokimab in Participants of 6 to 11 Years of Age
Research Team
U
US GSK Clinical Trials Call Center
E
EU GSK Clinical Trials Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here